menu
    • menu
    [{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Protein Sciences Corporation","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"Diamyd","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Protein Sciences Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Diamyd Medical AB \/ Protein Sciences Corporation"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"JDRF","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ JDRF","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ JDRF"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"DiaUnion","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ DiaUnion","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ DiaUnion"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Icon Plc"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GAD-alum","moa":"Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gamma-Aminobutyric Acid","moa":"||GABA receptor","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GAD-alum","moa":"||Th1","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"},{"orgOrder":0,"company":"Diamyd Medical AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"SWEDEN","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Colecalciferol","moa":"||Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Diamyd Medical AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Intralymphatic Injection","sponsorNew":"Diamyd Medical AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Diamyd Medical AB \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Diamyd Medical AB

    Menu

    Diamyd Medical AB

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical Confirms Advances for Accelerated Approval of Diamyd®

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Srage 3 Diabetes Mellitus, Type 1.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    January 10, 2025

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical Aligns with FDA on Key Elements for an Accelerated Approval Process

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    December 13, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Recruitment Milestone Reached in Diamyd® Phase 3 Trial

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    December 04, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical hits a recruitment milestone in DIAGNODE-3 Phase 3 trial

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1 in 12-28 year old patients.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    November 21, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical Pursues Accelerated Approval for Type 1 Diabetes Precision Medicine

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    September 09, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical Receives Second FDA Fast Track Designation for Diamyd® in Type 1 Diabetes

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    July 18, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®

    Details : Diamyd (rhGAD65) is recombinant human glutamic acid decarboxylase formulated in Alhydrogel®. It is being evaluated for the treatment of Diabetes Mellitus, Type 1.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    February 15, 2024

    Lead Product(s) : GAD-alum,Vitamin D3

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : DiaUnion

    Deal Size : Undisclosed

    Deal Type : Partnership

    DEALS_DEV arrow-down

    Diamyd Medical Partners with DiaUnion to Recruit Participants for Type 1 Diabetes Prevention Trial

    Details : The partnership aims to identify participants for the DiaPrecise trial, an open-label trial evaluating the safety, feasibility and immune response of intralymphatic injections of Diamyd (recombinant human glutamic acid decarboxylase) in children at risk ...

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    July 11, 2023

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : DiaUnion

    Deal Size : Undisclosed

    Deal Type : Partnership

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Registrational Phase III Trial in Type 1 Diabetes with Diamyd® Expands to the US

    Details : Diamyd® is an antigen-specific immunotherapy for the treatment of autoimmune diabetes. Diamyd® is based on the protein GAD65, an endogenous antigen involved in the pathology of autoimmune diabetes.

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Inapplicable

    May 09, 2023

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed

    Diamyd Medical AB

    Sweden arrow
    BioTrinity 2025
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Study Phase : Phase III

    Sponsor : JDRF

    Deal Size : $5.0 million

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Diamyd Medical Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes

    Details : The collaboration aims to support Diamyd Medical's ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd (recombinant human glutamic acid decarboxylase), an antigen-specific immunotherapy for the preservation of endogeno...

    Product Name : Diamyd

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    April 04, 2023

    Lead Product(s) : GAD-alum

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Sponsor : JDRF

    Deal Size : $5.0 million

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth